Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Helleberg, Marie (); Niemann, Carsten Utoft (); Moestrup, Kasper Sommerlund (); Kirk, Ole (); Lebech, Anne-Mette (); Lane, Clifford (); Lundgren, Jens (); Moestrup, Kasper ()
- Source:
Journal of Infectious Diseases. 10/1/2020, Vol. 222 Issue 7, p1103-1107. 5p.
- Additional Information
- Subject Terms:
- Abstract:
The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients. [ABSTRACT FROM AUTHOR]
